Abstract
Recent regulatory and policy changes may help to improve the affordability of some high-cost cancer treatments. However, larger systemic changes are needed to address the excessive growth in spending for cancer therapies and to ensure that patients and payers receive maximum value for their health care dollars.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / economics*
-
Antineoplastic Agents / therapeutic use
-
Drug Costs*
-
Drug Industry
-
Health Care Costs
-
Humans
-
Medicare
-
Negotiating
-
Neoplasms / drug therapy
-
Neoplasms / economics*
-
United States